Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility
Gabriele Antonarelli, Beatrice Taurelli Salimbeni, Antonio Marra, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 192, pp. 104148-104148
Closed Access | Times Cited: 15

Showing 15 citing articles:

EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer
Stefania Belli, Daniela Esposito, Claudia Maria Ascione, et al.
Cancer Letters (2024) Vol. 593, pp. 216968-216968
Open Access | Times Cited: 11
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer
Jamil Nehme, Sjors Maassen, Sara Bravaccini, et al.
The EMBO Journal (2025)
Open Access | Times Cited: 1
Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer
Masayuki Nagahashi, Yasuo Miyoshi
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3354-3354
Open Access | Times Cited: 6
Local Control of Advanced Breast Cancer—Debate in Multidisciplinary Tumor Board
Iuliana Pantelimon, Andra Maria Stancu, Simona Coniac, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 510-510
Open Access
Evaluating patients on CDK-4/6 inhibitor treatment for differences in treatment according to demographic variables
Sneha Rajendran, Marina Petruzzi, Dianxu Ren, et al.
Future Oncology (2025), pp. 1-4
Closed Access
Therapeutic Response After 10 Months of Treatment With Letrozole and Palbociclib in a Postmenopausal Woman With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Metastatic Breast Cancer and Skin Involvement
Ivan Bivolarski
Cureus (2025)
Open Access
Aberrant cytoplasmic localization of MLH1 characterizes a sub-clonal breast cancer cell population that seeds recurrence
Aloran Mazumder, J T DeWitt, Elena Oropeza, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
The “lows”: update on ER-low and HER2-low breast cancer
Nicola Fusco, G. Viale
The Breast (2024) Vol. 78, pp. 103831-103831
Open Access | Times Cited: 2
Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real‐world evidence in metastatic breast cancer
Binliang Liu, Zheyu Hu, Ning Xie, et al.
Cancer Innovation (2024) Vol. 3, Iss. 6
Open Access | Times Cited: 1
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
Sònia Pernas, Esther Sanfeliu, Guillermo Villacampa, et al.
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 1
CDK4/6 inhibitors promote senescence-associated lysosomal alterations and enhance sensitivity to lysosomotropic agents in breast cancer
Jamil Nehme, Sjors Maassen, Sara Bravaccini, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume
Bediz Kurt İnci, Pınar Kubilay Tolunay, Şura Öztekin, et al.
Current Oncology (2024) Vol. 31, Iss. 10, pp. 5722-5729
Open Access
Using bioinformatics and artificial intelligence to map the cyclin-dependent kinase 4/6 inhibitor biomarker landscape in breast cancer
Kim Wager, Yao Wang, Andrew T. F. Liew, et al.
Future Oncology (2024), pp. 1-19
Open Access
RERE-AS1 enhances the effect of CDK4/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway
Zhidong Huang, Kaixin Lou, Mengyang Qi, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access
Recent advancements in biomarkers and molecular diagnostics in hormonal receptor‐positive breast cancer
Yihong Wang, Liu Liu, Stephanie L. Graff, et al.
Histopathology (2024)
Closed Access
Page 1

Scroll to top